Table. 3—

Studies performed with hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) pressurised metered-dose inhaler extra-fine aerosol

Asthma patients	First author [ref.]	Protocol	Primary outcome	Secondary outcomes
Moderate to severe uncontrolled with ICS	Aubier [152]	HFA-BDP 800 μg per day; n = 101 CFC-FP 1000 μg per day; n = 97 8 weeks	Peak flow	Symptoms
	Busse [146]	HFA-BDP 100–800 μg per day; n = 50 to 56 CFC-BDP 100–800 μg per day; n = 52 to 59 6 weeks	FEV₁	FEV₁ FVC FEF_25–75% Symptoms
	Fairfax [153]	HFA-BDP 400 μg per day; n = 88 CFC-FP 400 μg per day; n = 84 6 weeks	Peak flow	Symptoms HRQoL
	Juniper [155]	HFA-BDP 400 μg per day; n = 112 CFC-BDP 800 μg per day; n = 115 3 months	HRQoL	Symptoms
	Fowler [154]	HFA-BDP 400 μg per day; n = 19 FP/salmeterol DPI 200/100 μg per day; n = 20 3 months	PD₂₀ methacholine	Symptoms HRQoL
Moderate to severe stable with ICS	Fireman [156]	HFA-BDP; n = 354 CFC-FP; n = 119 12 months	Peak flow	Symptoms
	Juniper [157]	Open-labelHFA-BDP; n = 354 CFC-BDP; n = 119 12 months	HRQoL	Symptoms
Moderate to severe uncontrolled with ICS+LABA	Molimard [158]	Open-label HFA-BDP 800 μg per day; n = 149 FP DPI 1000 μg per day; n = 162 BUD DPI 1600 μg per day; n = 149	Control of asthma	Symptoms
	Thongngarm [75]	Open-label HFA-BDP 320 μg per day; n = 20 CFC-FP 330 μg per day; n = 10 3 months	Nitrogen washout (closing volume)	Symptoms

ICS: inhaled corticosteroid; LABA: long-acting β-agonist; FP: fluticasone propionate; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF_25–75%: mean forced expiratory flow between 25% and 75% of FVC; HRQoL: health-related quality of life; DPI: dry powder inhaler; PD₂₀: provocative dose causing a 20% fall in FEV₁; BUD: budesonide.